Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury

• Published in: Osteoporosis international 2023-04, Vol.34 (4), p.741-748
• Main Authors: Cirnigliaro, Christopher M., La Fountaine, Michael F., Parrott, J. Scott, Kirshblum, Steven C., Sauer, Susan J., Shapses, Sue A., McClure, Isa A., Bauman, William A.
• Format: Article
• Language: English
• Subjects: Bone Density; Bone Density Conservation Agents - pharmacology; Bone Density Conservation Agents - therapeutic use; Bone Diseases, Metabolic - drug therapy; Bone mineral density; Demineralization; Denosumab - adverse effects; Dual energy X-ray absorptiometry; Endocrinology; Epiphysis; Femur; Hip; Humans; Knee; Lower Extremity; Medicine; Medicine & Public Health; Metaphysis; Monoclonal antibodies; Original Article; Orthopedics; Osteoporosis; Placebos; Rheumatology; Skeleton; Spinal cord injuries; Spinal Cord Injuries - complications; Spinal Cord Injuries - drug therapy; Tibia
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-023-06679-w

Summary Twelve months following discontinuation of denosumab, the percent decrease in mean bone mineral density (BMD) values at the hip and knee regions were similar between both the denosumab and placebo groups . These findings emphasize the need for additional trials to understand the effect of continued administration of denosumab after subacute spinal cord injury (SCI) to avoid this demineralization. Objective To determine changes in BMD 1 year after denosumab was discontinued in participants with subacute SCI who had drug treatment initiated within 90 days post SCI and continued for 1 year. Methods Fourteen participants who completed a randomized, double-blinded, placebo-controlled drug trial (parent study: denosumab 60 mg (Prolia, Amgen Inc., n  = 8) or placebo ( n  = 6); administered at baseline, 6, and 12 months) were followed 12 months after the 18 months from baseline primary end point was completed. The BMD of skeletal regions below the SCI at higher risk of fracture was measured [total hip, distal femur epiphysis (DFE), distal femur metaphysis (DFM), and proximal tibia epiphysis (PTE)] by dual energy X-ray absorptiometry. Results The percent decreases in mean BMD values at all regions of the hip and knee from 18 to 30 months were similar in both the denosumab and placebo groups. However, at 30 months, the absolute values for mean BMD remained significantly higher in the drug treatment than that of the placebo group at the DFM ( p  = 0.03), DFE ( p  = 0.04), and PTE ( p  = 0.05). Conclusions In persons with SCI who initiated denosumab treatment during the subacute injury phase and maintained treatment for 1 year, the discontinuation of drug resulted in percent loss of mean BMD similar to that of the placebo group, with absolute mean BMD values at the knee regions at the 12-month follow-up visit significantly higher in the drug treatment than those in the placebo group. These data underscore the need to study continued administration of denosumab after subacute SCI to avoid marked demineralization in the sublesional skeleton upon discontinuation of this agent.